Tag Archives: Psychoactive drugs

12Jan/22

Cantourage brings first Ugandan medical cannabis to Germany through partnership with Israel’s Together Pharma

European medical cannabis leader Cantourage and Israeli medical cannabis producer Together Pharma (TASE: TGTR) have formed a partnership that will see the first Ugandan medical cannabis brought to Germany. From today, pharmacies and patients throughout Germany will have access to two of Together Pharma’s THC genetics: Glueberry OG® and Power Plant. Continue reading

10Jun/21

Curaleaf’s Select Brand And Rolling Stone Announce Strategic Partnership

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer products in cannabis, is proud to announce a first-of-its-kind strategic partnership between its Select brand and legendary music and culture authority Rolling Stone. Together, the leading lifestyle brand in cannabis joins the most prominent voice in music and pop culture to celebrate the symbiotic relationship between music and cannabis. The long term partnership leverages Select’s resources and experience creating progressive, industry-leading cannabis products alongside Rolling Stone, whose DNA lives at the intersection of music’s past, present and future. Continue reading

28May/21

Latest global data finds nearly 8 million deaths from smoking in 2019, and 90% of new smokers addicted by age 25

The most comprehensive data on global trends in smoking highlight its enormous global health toll. The number of smokers worldwide has increased to 1.1 billion in 2019, with tobacco smoking causing 7.7 million deaths – including 1 in 5 deaths in males worldwide. Continue reading

08Aug/20

Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.1 SPRAVATO® is the first and only approved medicine that has been shown to reduce depressive symptoms within 24 hours,1 providing a new option for significant symptom relief until a longer-term, comprehensive treatment plan can take effect. Read more

09Nov/17

Colombia seizes 12 tons of cocaine, its biggest ever haul

APARTADO, COLOMBIA (NOVEMBER 08, 2017) (MUTE) (COLOMBIAN GOVERNMENT TV) – Police seized more than 12 tons (11 metric tonnes) of cocaine from Colombia’s top crime gang on Wednesday (November 8), the biggest haul ever in the nation’s long-running fight against drug trafficking, President Juan Manuel Santos said. Continue reading

08Oct/17

Spain seizes massive cocaine haul in Atlantic

CADIZ, SPAIN (OCTOBER 7, 2017) (GUARDIA CIVIL) – Spanish authorities seized 3.8 tonnes of cocaine found in a hidden compartment of a tug-boat on Saturday, (October 7). The massive drugs haul was part of an international operation in the Atlantic Ocean. Continue reading

07Feb/17

Vaping teens are using e-cigarettes for ‘dripping,’ according to Yale study

A Yale study has found that one in four teens have tried an alternative vaping technique which health experts warn is potentially dangerous.
Continue reading

17Dec/16

U.S. surgeon general claims e-cigarettes harmful for young people

The U.S. surgeon general is calling for action on the use of e-cigarettes among young people, and has released a report emphasizing its harmful effects.
Continue reading